Monoclonal antibody preparations

Stabilizing monoclonal antibodies with low or neutral pI using ionic excipients and sugars at pH 5.5 to 7.5 addresses colloidal instability, ensuring stability and reducing agglomeration, particularly at commercially relevant concentrations.

JP7590125B2Active Publication Date: 2024-11-26MEDIMMUNE LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2020100961
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-03-01
Filing Date
2020-06-10
Publication Date
2024-11-26
Estimated Expiration
2038-02-28

AI Technical Summary

Technical Problem

Monoclonal antibodies with low or neutral isoelectric points (pI) face colloidal instability when formulated outside the pH range of 5.5 to 7.5, leading to issues such as agglomeration, precipitation, and increased fragmentation and oxidation, which are exacerbated at commercially desirable concentrations.

Method used

Formulations comprising monoclonal antibodies with low or neutral pI are stabilized by incorporating ionic excipients like salts and sugars, maintaining a pH between 5.5 and 7.5, which shield opposite charges on the protein surface and reduce self-association.

Benefits of technology

The formulations achieve significant reduction in agglomeration rates and maintain stability, even at high antibody concentrations, while avoiding instability associated with neutral or basic pH.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007590125000006
    Figure 0007590125000006
  • Figure 0007590125000007
    Figure 0007590125000007
  • Figure 0007590125000008
    Figure 0007590125000008
Patent Text Reader

Abstract

To provide formulations of monoclonal antibodies.SOLUTION: The present invention provides a formulation comprising: (i) a monoclonal antibody; and (ii) an ionic excipient; where the monoclonal antibody is present at a concentration of about 50 mg / ml or more (e.g., about 50 mg / ml to about 200 mg / ml), the ionic excipient is present at a concentration of about 50 to about 150 mM, and the formulation has a pH of 5.5 to 6.5. A formulation comprises: i. a monoclonal antibody; and ii. an ionic excipient; where the monoclonal antibody is present at a concentration of about 50 mg / ml or more, the ionic excipient is present at a concentration of about 50 to about 150 mM, and the formulation has a pH of 5.5 to 7.5.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to antibody formulations, particularly monoclonal antibody formulations and uses thereof. In particular, it relates to providing improved colloidal stability of antibody formulations. [Background technology]

[0002] The pharmaceutical pH range for protein formulations is preferably between pH 5.5 and pH 7.5. The isoelectric point (pI) of some monoclonal antibodies allows these molecules to be formulated in unique Present the challenge.

[0003] Colloidal instability at the pI of a molecule is due to the lack of electrostatic charge on the molecule. The lack of electrostatic charge in the nucleosome leads to closer protein-protein interactions that result in physical instability. (so-called "self-association"). For this reason, the pH of protein formulations is typically is chosen to be at least one pH unit away from the protein pI. This is because the colloid Provides stability and therefore prevents aggregation, precipitation, opalescence, phase separation, and / or particle formation. The purpose is to prevent physical instability.

[0004] Therefore, according to the "one pH unit away" rule, a low or neutral pI, e.g. pH 5 Antibodies with a pI between 5.5 and pH 7.5 should be used in formulations with a pH outside the range of 5.5 to 7.5. However, outside this range, further instability has been observed. At more acidic pH, increased fragmentation rates, decreased conformational stability, and increased aggregation can occur. At more basic pH, an increase in oxidation, deamidation, and fragmentation can be observed. As well as the potential for incompatibility with glass containers.

[0005] The above instability is a concern when antibodies are present at commercially desirable concentrations, e.g., 50 mg / ml or greater. This is particularly problematic in antibody formulations such as those described above. Summary of the Invention [Problem to be solved by the invention]

[0006] Therefore, there is a need to provide improved formulations for antibodies with low or neutral pI. In particular, stable formulations for antibodies with low or neutral pI are particularly commercially desirable. There is a need to provide such formulations having antibody concentrations. [Means for solving the problem]

[0007] The present invention provides novel antibody formulations, particularly novel monoclonal antibody formulations. The formulation provides a means to improve the colloidal stability of antibodies with low or neutral pI. Therefore, the present invention adheres to the "one pH away" rule for providing colloidal stability. Thus, the present invention provides an alternative to the use of antibodies with low or neutral pI as an antibody. Thus, the present invention allows formulations to be made within 1 pH unit of the pI of the body. Such antibodies can be used to substantially avoid the instability associated with acidic or more basic pH. This allows for the formulation of commercially useful concentrations within a pH range of 5.5 to 7.5.

[0008] The present invention relates to: i. monoclonal antibodies; and ii. ionic excipients; The monoclonal antibody is provided in a concentration of about 50 mg / ml or more (e.g., about 50 The ionic excipient is present at a concentration of about 50 to about 1 Present at a concentration of 50 mM, the formulation has a pH of 5.5 to 7.5.

[0009] Thus, the present invention provides: i. monoclonal antibodies; and ii. ionic excipients; The present invention further provides a formulation comprising the monoclonal antibody, the monoclonal antibody being at about 50 mg / ml or more (e.g., about 50 mg / ml to about 200 mg / ml), and this ionic excipient is present at a concentration of about 50 150 mM, and the formulation has a pH of 5.5 to 7.5; The aggregation rate of clonal antibodies was compared to the aggregation rate of the same antibodies in the same formulation without ionic excipients. Comparatively low.

[0010] The formulations of the present invention may be used in the preparation of antibodies having a low or neutral pI, for example, in the range of pH 5.5 to pH 7.5. The present invention is particularly useful for: i. Monoclonal antibodies with a low or neutral pI (e.g., 5.5 to 7.5); and ii. ionic excipients; The monoclonal antibody is provided in a concentration of about 50 mg / ml or more (e.g., about 50 The ionic excipient is present at a concentration of about 50 to about 1 Present at a concentration of 50 mM, the formulation has a pH of 5.5 to 7.5.

[0011] Thus, the present invention relates to a formulation comprising: i. Monoclonal antibodies with a low or neutral pI (e.g., 5.5 to 7.5); and ii. ionic excipients; The present invention further provides a formulation comprising the monoclonal antibody, the monoclonal antibody being at about 50 mg / ml or more (e.g., about 50 mg / ml to about 200 mg / ml), and this ionic excipient is present at a concentration of about 50 150 mM, and the formulation has a pH of 5.5 to 7.5; The aggregation rate of clonal antibodies was measured using the same antibody formulated in the same formulation without ionic excipients. The aggregation rate is lower than that of

[0012] In one embodiment, the monoclonal antibody has a pI in the range of 5.5 to 7.5. In one embodiment, the monoclonal antibody has a pI in the range of 6.0 to 7.5. In one embodiment, the monoclonal antibody has a pI in the range of 6.3 to 7.5. Local antibodies have a pI in the range of 6.4 to 7.5. A low to neutral pI is not a good indicator of the presence of oppositely charged (positive and negative amine) groups on the protein. There is a net balance of amino acid side chains (carboxylate groups) or different domains. The cations produced by the protein are generally oppositely charged within the pH range of 5.5 to 7.5. Similarly, without wishing to be bound by theory, it is believed that the ionic Active excipients shield these opposing attractive charges and therefore have a pI within this range. Therefore, the present invention provides a method for colloidal stabilization of a protein. The use of ion exchange in antibody formulations to change the charge state or distribution of the antibody in the formulation The present invention provides the use of a colloidal excipient that colloidally stabilizes an antibody in a formulation. There is further provided the use of an ionic excipient in an antibody formulation for the purpose of

[0013] In one embodiment, the monoclonal antibody is present in a formulation described herein at about 75 mg / ml or more. In one embodiment, the glycerol is present in a concentration of about 75 mg / ml to about 200 mg / ml. In the formulations described herein, the monoclonal antibody is present at about 100 mg / ml or more (e.g., In one embodiment, the monoclonal antibody is present in a concentration of about 100 mg / ml to about 200 mg / ml. The monoclonal antibody is present in the formulations described herein at a concentration of about 100 mg / ml to about 165 mg / ml. In one embodiment, the monoclonal antibody is present at a concentration of about 100 mg / ml. do.

[0014] In one embodiment, the ionic excipient is present at a concentration of about 75 mM to about 100 mM. In one embodiment, the ionic excipient is present at a concentration of about 75 mM. The excipients are present at a concentration of about 80 mM.

[0015] In one embodiment, the monoclonal antibody is an IgG1 or IgG4 monoclonal antibody. Most preferably, the monoclonal antibody is an IgG4 monoclonal antibody. IgG4 antibodies typically have a low or neutral pI. Thus, the present invention provides: i. IgG4 monoclonal antibody; and ii. ionic excipients; The monoclonal antibody is provided in a concentration of about 50 mg / ml or more (e.g., about 50 The ionic excipient is present at a concentration of about 50 to about 1 Present at a concentration of 50 mM, the formulation has a pH of 5.5 to 7.5.

[0016] Thus, the present invention relates to a formulation comprising: i. IgG4 monoclonal antibody; and ii. ionic excipients; The present invention further provides a formulation comprising the monoclonal antibody, the monoclonal antibody being at about 50 mg / ml or more (e.g., about 50 mg / ml to about 200 mg / ml), and this ionic excipient is present at a concentration of about 50 150 mM, and the formulation has a pH of 5.5 to 7.5; The aggregation rate of clonal antibodies was compared to the aggregation rate of the same antibodies in the same formulation without ionic excipients. Comparatively low.

[0017] In one embodiment, the formulations described herein have a pH range of about pH 5.5 to about pH 6.5. In one embodiment, the formulations described herein have a pH in the range of about pH 5.7 to about pH 6.3. In one embodiment, the formulations described herein have a pH ranging from about pH 5.7 to about pH 6. The preferred formulation has a pH in the range of about 5.1. The preferred formulation has a pH of about 5.8. Other preferred formulations has a pH of about 6.0.

[0018] In one embodiment, the ionic excipient is a charged amino acid. The excipient is lysine. In another embodiment, the ionic excipient is arginine.

[0019] In one embodiment, the ionic excipient is a salt. Thus, the present invention provides a method for the preparation of a compound comprising: i. a monoclonal antibody as defined anywhere herein; and ii. salt; The monoclonal antibody is provided in a concentration of about 50 mg / ml or more (e.g., about 50 The salt is present at a concentration of about 50 to about 150 mM. The formulation has a pH of 5.5 to 7.5.

[0020] Thus, the present invention provides: i. a monoclonal antibody as defined anywhere herein; and ii. salt; The present invention further provides a formulation comprising the monoclonal antibody, the monoclonal antibody being at about 50 mg / ml or more (e.g., The salt is present at a concentration of about 50 to about 150 mg / ml. M, the formulation having a pH of 5.5 to 7.5; The aggregation rate of the antibody is lower compared to the aggregation rate of the same antibody in the same formulation without salt.

[0021] In one embodiment, the salt is present at a concentration of about 75 mM to about 100 mM. , the salt is present at a concentration of about 75 mM or about 80 mM.

[0022] In one embodiment, the salt is, for example, at a concentration of about 75 mM to about 100 mM, suitably about 75 mM is the concentration of NaCl.

[0023] In one embodiment, the salt is, for example, at a concentration of about 75 mM to about 100 mM, suitably about 80 mM The concentration of arginine hydrochloride is

[0024] In one embodiment, the formulation further comprises a sugar. Among other known advantages, the presence of sugar enhances the This means that preferred formulations are isotonic or nearly isotonic (e.g., 24 In one embodiment, the osmolality of the infusion is preferably 0 to 500 mOsm / kg. The ionic excipient is a salt and the formulation further comprises a sugar.

[0025] In one embodiment, the formulation further comprises a sugar, and the ionic excipient is about 75 mM to about 150 mM In one embodiment, the formulation further comprises a sugar and the ionic excipient is present at a concentration ranging from about In one embodiment, the formulation further comprises a sugar. The sugars are present at concentrations ranging from about 100 mM to 140 mM, and the ionic excipients are present at about 70 mM. It is present in concentrations ranging from 5 mM to 100 mM.

[0026] Thus, the present invention provides: i. A monoclonal antibody as defined anywhere herein; ii. An ionic excipient (e.g., a salt) as defined anywhere herein; iii. Sugar as defined anywhere herein; The monoclonal antibody is provided in a concentration of about 50 mg / ml or more (e.g., about 50 The ionic excipient is present at a concentration of about 50 to about 1 It is present at a concentration of 50 mM and the formulation has a pH of 5.5 to 7.5. , preferably about 75 mM to about 150 mM, more preferably about 75 mM to about 100 mM. It exists in concentrations ranging from

[0027] Thus, the present invention provides: i. a monoclonal antibody as defined anywhere herein; and ii. An ionic excipient (e.g., a salt) as defined anywhere herein; iii. Sugar as defined anywhere herein; The present invention further provides a formulation comprising the monoclonal antibody, the monoclonal antibody being at about 50 mg / ml or more (e.g., about 50 mg / ml to about 200 mg / ml), and this ionic excipient is present at a concentration of about 50 150 mM, and the formulation has a pH of 5.5 to 7.5; The aggregation rate of clonal antibodies was compared to the aggregation rate of the same antibodies in the same formulation without ionic excipients. The ionic excipient is preferably about 75 mM to about 150 mM, more preferably is present at a concentration ranging from about 75 mM to about 100 mM.

[0028] In one embodiment, the sugar is trehalose. In another embodiment, the sugar is sucrose. For example, the sugar is present at a concentration of about 100 mM to about 140 mM, suitably at a concentration of about 120 mM. There is.

[0029] In one embodiment, the formulation further comprises one or more buffering agents. The buffer or buffers are histidine-containing buffers. Several buffers are available, including histidine succinate, histidine acetate, histidine citrate, and histidine chloride. In one embodiment, the buffer is selected from the group consisting of one or more of histidine, histidine, or histidine sulfate. The buffers are histidine, histidine hydrochloride, or a combination of both (histidine In one embodiment, the one or more buffering agents is L-histidine / histidine hydrochloride. For example, the buffering agent may be about 10 mM to about 5 mM L-histidine hydrochloride monohydrate. The buffer may be at a concentration of about 0 mM, suitably at a concentration of about 30 mM. It should be understood that the buffer may be an ionic excipient. In this embodiment, the concentration of the buffer is greater than 50 mM, i.e. The concentration of ionic excipients should be consistent with that disclosed in the document. In this embodiment, the ionic excipient also acts as a buffer in the formulation. A buffer may or may not be present.

[0030] In one embodiment, the formulation further comprises a surfactant. For example, polysorbates including polysorbate 80.

[0031] In one embodiment, the formulation further comprises a sugar and one or more buffering agents. In the present invention, the ionic excipient is a salt and the formulation further comprises a sugar and one or more buffering agents. .

[0032] In one embodiment, the formulation further comprises a surfactant, a sugar, and one or more buffering agents. In one embodiment, the ionic excipient is a salt and the formulation comprises a surfactant, a sugar, and one or more The composition further comprises a buffer or buffers.

[0033] Thus, the present invention provides: i. A monoclonal antibody as defined anywhere herein; ii. An ionic excipient (e.g., a salt) as defined anywhere herein; iii. Sugar as defined anywhere herein; iv. one or more buffering agents as defined anywhere herein; and v. optionally a surfactant, as defined anywhere herein; The monoclonal antibody is provided in a concentration of about 50 mg / ml or more (e.g., about 50 The ionic excipient is present at a concentration of about 50 to about 1 Present at a concentration of 50 mM, the formulation has a pH of 5.5 to 7.5.

[0034] Thus, the present invention provides: i. a monoclonal antibody as defined anywhere herein; and ii. An ionic excipient (e.g., a salt) as defined anywhere herein; iii. Sugar as defined anywhere herein; iv. one or more buffering agents as defined anywhere herein; and v. an optional surfactant as defined anywhere herein; The present invention further provides a formulation comprising the monoclonal antibody, the monoclonal antibody being at about 50 mg / ml or more (e.g., about 50 mg / ml to about 200 mg / ml), and this ionic excipient is present at a concentration of about 50 150 mM, and the formulation has a pH of 5.5 to 7.5; The aggregation rate of clonal antibodies was compared to the aggregation rate of the same antibodies in the same formulation without ionic excipients. Comparatively low.

[0035] The formulations described herein may also contain, for example, one or more sugars, salts, amino acids, polyamines, One or more additional excipients may also be included, including but not limited to, a chelating agent, an emulsifier, and / or a preservative. It may include.

[0036] One preferred formulation provided by the present invention is 150 mg / ml antibody, 50 mM Sodium acetate / acetic acid, 106 mM trehalose anhydrous, 70 mM sodium chloride 0.05% (w / v) polysorbate 80, and the formulation has a pH of 5.8. The antibody in the formulation is preferably an anti-GM-CSF-Rα IgG4 antibody, more preferably or having the VH and VL sequences of the CAM-3001 antibody as described herein. The antibody in the formulation is preferably an anti-GM-CSF-Rα IgG4 antibody. and an anti-GM-CSF antibody having the same six CDRs as the CAM-3001 antibody as described herein. -Rα IgG4 antibody.

[0037] One preferred formulation provided by the present invention is 150 mg / ml antibody, 50 mM sodium acetate, 85 mM sodium chloride, and 0.01% polysorbate 80 and the formulation has a pH of pH 5.5. The antibody in the formulation is preferably an anti-IL-1 -13 IgG4 antibody, more preferably the CAT-354 antibody as described herein. The antibody in this formulation is an anti-IL-13 IgG4 antibody having the VH and VL sequences of and preferably has the same six CDRs as the CAT-354 antibody as described herein. It is an anti-IL-13 IgG4 antibody that inhibits IL-13.

[0038] The formulation of the present invention is preferably a pharmaceutical formulation.

[0039] The present invention relates to a pharmaceutical formulation as described anywhere herein for use as a medicament. to provide.

[0040] The present invention relates to a pharmaceutical composition as described anywhere herein for use in the treatment of a disease. The present invention provides a method for treating

[0041] The present invention includes administering to a subject a pharmaceutical formulation as described anywhere herein. Also provided are methods of treating a disease in a subject. Also provided herein are methods of treating a subject by administering to the subject a therapeutically effective amount of a pharmaceutical formulation. will be done.

[0042] In one embodiment, the subject is a human.

[0043] The disease to be treated will depend on the particular antibody contained in the formulation. In one embodiment, The disease is cancer. The disease is diabetes, cardiovascular disease, infectious diseases, rheumatoid arthritis, vasculitis, megalomaniasis, Giant cell arthritis, glomerulonephropathy, lupus nephritis , uveitis, atopic dermatitis, liver cirrhosis, psoriatic arthritis, chronic obstructive pulmonary disease, severe asthma The disease may be selected from the group consisting of pulmonary edema, neutrophilic asthma, and myeloid leukemia.

[0044] The present invention relates to a method for preparing a formulation as defined herein or a composition as defined herein using only sterile water. The present invention provides a lyophilized cake that can be reconstituted into a pharmaceutical formulation. Also provided herein is a formulation capable of forming a lyophilized cake, the lyophilized cake being , a formulation as defined herein or a pharmaceutical formulation as defined herein using only sterile water. can be reconstructed into The present invention provides, for example, the following items. (Item 1) A formulation comprising: i. monoclonal antibodies; and ii. ionic excipients; wherein said monoclonal antibody is present at a concentration of about 50 mg / ml or greater, said ionic excipient is present at a concentration of about 50 to about 150 mM, and said formulation has a pH of 5.5 to 7.5. (Item 2) A formulation comprising: i. monoclonal antibodies; and ii. ionic excipients; wherein said monoclonal antibody is present at a concentration of about 50 mg / ml or greater, said ionic excipient is present at a concentration of about 50 to about 150 mM, said formulation having a pH of 5.5 to 7.5; and wherein the aggregation rate of said monoclonal antibody in said formulation is reduced compared to the aggregation rate of the same antibody in the same formulation without the ionic excipient. (Item 3) 3. The formulation according to item 1 or 2, wherein the monoclonal antibody has a pI in the range of pH 5.5 to pH 7.5. (Item 4) 4. The formulation according to any one of items 1 to 3, wherein the monoclonal antibody has a pI in the range of pH 6.0 to pH 7.5. (Item 5) 4. The formulation according to any one of items 1 to 3, wherein the monoclonal antibody has a pI in the range of pH 6.4 to pH 7.5. (Item 6) 6. The formulation according to any one of items 1 to 5, wherein the monoclonal antibody is an IgG4 monoclonal antibody. (Item 7) 7. The formulation according to any one of items 1 to 6, wherein the monoclonal antibody is present in the formulation at a concentration of about 100 mg / ml to about 200 mg / ml. (Item 8) 8. The formulation of item 7, wherein the monoclonal antibody is present in the formulation at a concentration of about 100 mg / ml. (Item 9) 9. The formulation according to any one of items 1 to 8, having a pH in the range of about pH 5.5 to about pH 6.5. (Item 10) 9. The formulation according to any one of items 1 to 8, having a pH in the range of about pH 5.7 to about pH 6.3. (Item 11) 9. The formulation according to any one of items 1 to 8, having a pH in the range of about pH 5.7 to about pH 6.1. (Item 12) 12. The formulation according to item 11, having a pH of about pH 6.0. (Item 13) 13. The formulation according to any one of items 1 to 12, wherein the ionic excipient is a salt. (Item 14) 14. The formulation of item 13, wherein the salt is NaCl. (Item 15) 14. The formulation of item 13, wherein the salt is arginine hydrochloride. (Item 16) 14. The formulation of item 13, wherein the salt is lysine hydrochloride. (Item 17) 17. The formulation according to any one of items 1 to 16, wherein the ionic excipient is present in a concentration of about 75 mM to about 100 mM. (Item 18) 18. The formulation of item 17, wherein the ionic excipient is present in a concentration of about 80 mM. (Item 19) 19. The formulation according to any one of items 1 to 18, further comprising a sugar. (Item 20) 20. The formulation of item 19, wherein the sugar is trehalose. (Item 21) 20. The formulation of item 19, wherein the sugar is sucrose. (Item 22) 22. The formulation according to any one of items 19 to 21, wherein the sugar is present in a concentration of about 100 mM to about 140 mM. (Item 23) 23. The formulation of item 22, wherein the sugar is present at a concentration of about 120 mM. (Item 24) 24. The formulation according to any one of items 1 to 23, further comprising one or more buffering agents. (Item 25) 25. The formulation of item 24, wherein the one or more buffering agents are selected from histidine, histidine hydrochloride, and histidine / histidine hydrochloride. (Item 26) 26. The formulation of item 25, wherein the one or more buffering agents is L-histidine / L-histidine hydrochloride monohydrate. (Item 27) 27. The formulation according to any one of items 24 to 26, wherein the one or more buffering agents are present in a concentration of about 10 mM to about 50 mM. (Item 28) 28. The formulation of item 27, wherein the one or more buffering agents are present at a concentration of about 30 mM. (Item 29) 29. The formulation according to any one of items 1 to 28, further comprising a surfactant. (Item 30) 30. The formulation of item 29, wherein the surfactant is a polysorbate. (Item 31) 31. The formulation of item 30, wherein the surfactant is polysorbate 80. (Item 32) 32. The formulation according to any one of items 29 to 31, wherein the surfactant is present in the formulation at a concentration of about 0.02% (w / v) to about 0.07% (w / v). (Item 33) Item 3. The surfactant is present in the formulation at a concentration of about 0.04% (w / v). 2. The formulation according to claim 2. (Item 34) 34. The formulation according to any one of items 1-33, further comprising one or more additional excipients including, for example, one or more sugars, salts, amino acids, polyols, chelating agents, emulsifiers, and / or preservatives. (Item 35) 2. The formulation of item 1, comprising 150 mg / ml of anti-IL-13 IgG4 antibody, 50 mM sodium acetate, 85 mM sodium chloride, and 0.01% polysorbate 80, said formulation having a pH of pH 5.5. (Item 36) 36. The formulation of item 35, wherein the antibody has the six CDR sequences of CAT-354 as shown in Figure 1-1 and Figure 1-2. (Item 37) 36. The formulation of item 35, wherein the antibody has the VH and VL sequences of CAT-354 shown in Figure 1-1 and Figure 1-2. (Item 38) 2. The formulation of item 1, comprising 150 mg / ml anti-GM-CSF-Rα IgG4 antibody, 50 mM sodium acetate / acetic acid, 106 mM trehalose dihydrate, 70 mM sodium chloride, and 0.05% (w / v) polysorbate 80, said formulation having a pH of pH 5.8. (Item 39) 39. The formulation of item 38, wherein the antibody has the six CDR sequences of CAM-3001. (Item 40) 39. The formulation of item 38, wherein the antibody has the VH and VL sequences of CAM-3001. (Item 41) 41. The formulation according to any one of items 1 to 40, which is a pharmaceutical formulation. (Item 42) 42. The pharmaceutical formulation according to item 41 for use as a medicament. (Item 43) 42. A pharmaceutical formulation according to item 41 for use in the treatment of a disease. (Item 44) 42. A method for treating a disease in a subject, comprising administering to the subject the pharmaceutical preparation according to item 41. (Item 45) A lyophilized cake that can be reconstituted into the formulation according to any one of items 1 to 40 or the pharmaceutical formulation according to any one of items 41 to 43 using only sterile water. (Item 46) 44. A formulation that can be lyophilized to form a lyophilized cake and that can be reconstituted into the formulation according to any one of items 1 to 40 or the pharmaceutical formulation according to any one of items 41 to 43 using only sterile water. [Brief description of the drawings]

[0045] [Figure 1] Figure 1 shows the conversion of an IgG4 monoclonal antibody into half molecules. Figure 1-1 and Figure 1-2 show the sequences for the CAT-354 antibody. The VH and VL sequences are labeled and the six CDRs are underlined. [Figure 1-1(1)] Figure 1 shows the conversion of an IgG4 monoclonal antibody into half molecules. Figure 1-1 and Figure 1-2 show the sequences for the CAT-354 antibody. The VH and VL sequences are labeled and the six CDRs are underlined. [Figure 1-1(2)] Figure 1 shows the conversion of an IgG4 monoclonal antibody into half molecules. Figure 1-1 and Figure 1-2 show the sequences for the CAT-354 antibody. The VH and VL sequences are labeled and the six CDRs are underlined. [Figure 1-2(1)] Figure 1 shows the conversion of an IgG4 monoclonal antibody into half molecules. Figure 1-1 and Figure 1-2 show the sequences for the CAT-354 antibody. The VH and VL sequences are labeled and the six CDRs are underlined. [Figure 1-2(2)] Figure 1 shows the conversion of an IgG4 monoclonal antibody into half molecules. Figure 1-1 and Figure 1-2 show the sequences for the CAT-354 antibody. The VH and VL sequences are labeled and the six CDRs are underlined. [Figure 1-2(3)] Figure 1 shows the conversion of an IgG4 monoclonal antibody into half molecules. Figure 1-1 and Figure 1-2 show the sequences for the CAT-354 antibody. The VH and VL sequences are labeled and the six CDRs are underlined. [Figure 1-2(4)] Figure 1 shows the conversion of an IgG4 monoclonal antibody into half molecules. Figure 1-1 and Figure 1-2 show the sequences for the CAT-354 antibody. The VH and VL sequences are labeled and the six CDRs are underlined. [Diagram 2] FIG. 2 shows the effect of salt on the aggregation rate of IgG4 molecules. [Figure 3A] FIG. 3A shows the results of varying pH versus kD. [Figure 3B] FIG. 3B shows the results of varying pH on Kd in the presence of 100 mM salt. [Figure 4] Figure 4 shows the effect of salt on kD. Note that in general, colloidal stability decreases at pH 5, but increases at pH 6 and pH 7. [Diagram 5] FIG. 5 shows the aggregation rate data at 40° C. for formulations with and without 100 mM salt. [Figure 6] FIG. 6 shows the change in aggregation rate with pH for MEDI7814 formulations. [Figure 7] FIG. 7 shows the effect of ionic excipients on antibody aggregation rate at pH 6 (MEDI7814). [Figure 8]Figure 8 shows the MEDI8897 heavy chain nucleotide sequence and translation. The CDRs are underlined, the amino acid differences that form the allelic constant regions are circled, and the boundaries between the variable and constant regions are indicated by "|"). [Figure 9] Figure 9 shows the MEDI8897 light chain nucleotide sequence and translation. The CDRs are underlined and the boundaries between the variable and constant regions are indicated by "|"). [Figure 10] FIG. 10 shows the stability of MEDI8897 formulations at 5° C., 25° C., and 40° C. for 3 months. [Figure 11] FIG. 11 shows the effect of ionic excipients on antibody aggregation rate at pH 6 (MEDI578). [Figure 12] FIG. 12 shows the purity by size exclusion chromatography. [Figure 13] Figure 13 shows the reduction of sub-visible particles in formulations containing ionic excipients under thermal stress conditions. Colloidal stability is improved. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0046] Some monoclonal antibodies, especially IgG4 antibodies, are stable at physiological pH, i.e., in humans. These monoclonal antibodies have pIs close to the generally desirable pH for These difficulties may be particularly related to colloidal stability.

[0047] IgG4 monoclonal antibodies prevent complement activation and have bivalent reactivity In vivo half-molecule exchange between two IgG4 molecules to generate new IgG4 (one It is characterized by a structure that allows for the synthesis of one heavy chain and one light chain. See Figure 1. The IgG4 hinge is three amino acids shorter than the IgG1 hinge, and IgG4 has a covalent bond between the H chains. It has two cysteines available for binding interactions. [Aalberse and Sc huurman,“IgG4 breaking the rules,”Immuno logy 2002 105:9-19].

[0048] The present invention relates to a novel monoclonal antibody formulation, in particular a novel IgG4 monoclonal antibody formulation. The Company provides a novel IgG1 monoclonal antibody formulation.

[0049] The present invention relates to a method for producing a monoclonal antibody comprising: (i) a monoclonal antibody; and (ii) an ionic excipient (e.g., a salt). wherein the monoclonal antibody is present in a concentration of about 50 mg / ml or greater (e.g., about 5 0 mg / ml to about 200 mg / ml), and this ionic excipient is present in a concentration of about 50 to about Present at a concentration of 150 mM, the formulation has a pH of 5.5 to 7.5.

[0050] The present invention relates to a method for producing a monoclonal antibody comprising: (i) a monoclonal antibody; and (ii) an ionic excipient (e.g., a salt). and wherein the monoclonal antibody is at about 50 mg / ml or greater (e.g., , about 50 mg / ml to about 200 mg / ml), and this ionic excipient is present at a concentration of about The formulation has a pH of 5.5 to 7.5; The aggregation rate of monoclonal antibodies is the same as the aggregation rate of the same antibody in the same formulation without ionic excipients. is low compared to

[0051] The aggregation rate can be measured according to standard techniques, such as those described herein. Surprisingly, the formulations according to the invention have good stability and reduced self-aggregation. It has been shown to have low levels of aggregation, e.g., ≤2.0% when stored at room temperature for 3 months. Therefore, the present invention provides an antibody formulation having an antibody-binding domain capable of binding to a cellular component, the antibody being ... and the antibody being capable of binding to a cellular component. The present invention provides the use of an ionic excipient in a formulation to reduce self-aggregation of antibodies in the formulation. There is further provided the use of an ionic excipient in an antibody formulation to reduce

[0052] The formulations of the present invention are suitable for use with antibodies having a low or neutral pI, e.g., pH 5.5 to pH 7.5, p pH6.0~pH7.5, pH6.3~pH7.5, pH6.4~pH7.5, or pH Particularly useful are antibodies with a pI in the range of pH 6.5 to pH 7.5. The pI of the antibody is determined by standard This can be measured according to various techniques, for example by capillary isoelectric focusing (cIEF). Thus, the present invention provides: (i) a low or neutral pI (e.g., 5.5 to 7.5 and (ii) an ionic excipient; The monoclonal antibody has a concentration of about 50 mg / ml or more (for example, about 50 mg / ml to about 200 The ionic excipient is present at a concentration of about 50 to about 150 mM. and the formulation has a pH of 5.5 to 7.5. Thus, the present invention provides: (i) a low or (ii) a monoclonal antibody having a neutral pI (e.g., 5.5 to 7.5); and and a carboxylic excipient; (e.g., about 50 mg / ml to about 200 mg / ml), and this ionic excipient The excipient is present in a concentration of about 50 to about 150 mM, and the formulation has a pH of 5.5 to 7.5; The aggregation rate of a monoclonal antibody in a formulation is comparable to that of the same antibody in the same formulation without ionic excipients. This is low compared to the body's aggregation rate.

[0053] In one embodiment, the monoclonal antibody has a pI in the range of pH 6.4 to pH 7.5. In another embodiment, the monoclonal antibodies described herein are administered at a pH of about pH 5.5 to about pH 6.0, in the range of about pH 5.7 to about pH 6.0, or about pH 5.5, about pH 5.6, about pH H5.7, about pH5.8, about pH5.9, about pH6.0, about pH6.1, about pH6.2, It has a pI of about pH 6.3, about pH 6.4, or about pH 6.5. The pI of the monoclonal antibodies provided herein is between 5.7 and 6.0, more preferably about 5.8. or a pI of 6.0.

[0054] In one embodiment, the monoclonal antibody is an IgG1 or IgG4 monoclonal antibody. Most preferably, the monoclonal antibody is an IgG4 monoclonal antibody. Thus, the present invention provides an antibody that is capable of immunizing an individual against an antibody having: (i) a low or neutral pI (e.g., 5.5 to 7.5); and (ii) an ionic excipient; Monoclonal antibodies are about 50 mg / ml or more (for example, about 50 mg / ml to about 200 mg / ml ml), the ionic excipient is present at a concentration of about 50 to about 150 mM, The formulation has a pH of 5.5 to 7.5. Thus, the present invention provides: (i) a low or neutral pH (ii) an IgG4 monoclonal antibody having an I (e.g., 5.5 to 7.5); and The monoclonal antibody is further provided in a formulation comprising an ionic excipient; (e.g., about 50 mg / ml to about 200 mg / ml), and this ionic excipient The excipient is present in a concentration of about 50 to about 150 mM, and the formulation has a pH of 5.5 to 7.5; The aggregation rate of a monoclonal antibody in a formulation is comparable to that of the same antibody in the same formulation without ionic excipients. This is low compared to the body's aggregation rate.

[0055] In one embodiment, the monoclonal antibody is an anti-GM-CSF-Rα monoclonal antibody, Anti-IL-13 monoclonal antibody, anti-RSV monoclonal antibody, or anti-C5 / C5a In an exemplary embodiment, the monoclonal antibody is an IgG4 monoclonal antibody. In one embodiment, the antibody is a monoclonal antibody, such as an anti-GM-CSF-Rα monoclonal antibody. In one embodiment, the monoclonal antibody is CAM-3001. The antibody is MEDI8897.

[0056] A monoclonal antibody is a functional portion of an antibody, e.g., an antibody, or an antigen-binding fragment thereof, a variant Monoclonal antibodies include, but are not limited to, human antibodies. , humanized or chimeric antibodies, single chain antibodies, bispecific antibodies, epitope-binding fragments, e.g. For example, Fab, Fab', and F(ab')2, Fd, Fvs, single chain Fvs (scFv ), single chain antibodies, disulfide-linked Fvs (sdFv), VL domains or VH domains and fragments produced by a Fab expression library. ScFv molecules are known in the art and are described, for example, in U.S. Pat. Immunoglobulin or antibody molecules encompassed by the present disclosure are described in US Pat. IgA, IgE, IgM, IgD, IgA, and IgY. , class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA 2) or subclasses of immunoglobulin molecules. In a preferred embodiment, The clonal antibody is an IgG1 or IgG4 monoclonal antibody.

[0057] antibody concentration Suitably, the monoclonal antibody is present in the formulations described herein at, for example, about 50 mg / mL. ml ~ approx. 300mg / ml, approx. 50mg / ml ~ approx. 200mg / ml, approx. 100mg / m l ~ approx. 200mg / ml, approx. 100mg / ml ~ approx. 165mg / ml, approx. 100mg / m l to about 150 mg / ml, or about 50 mg / ml, about 75 mg / ml, about 100 mg / ml ml, approx. 105mg / ml, approx. 110mg / ml, approx. 115mg / ml, approx. 120mg / ml, approx. 125mg / ml, approx. 130mg / ml, approx. 135mg / ml, approx. 140mg / ml, approx. 145mg / ml, approx. 150mg / ml, approx. 155mg / ml, approx. 160mg / ml, about 165mg / ml, about 170mg / ml, about 175mg / ml, about 180mg / ml, about 185 mg / ml, about 190 mg / ml, about 195 mg / ml, or about 200 Present at commercially desirable concentrations of mg / ml (including values ​​and ranges within these ranges) .

[0058] Suitably, the monoclonal antibody is present in the formulations described herein at a concentration of from about 100 mg / ml to about Suitably, the monoclonal antibody is present in a concentration of 165 mg / ml. It is present in the formulation at a concentration of about 100 mg / ml.

[0059] pH Suitably, the formulations described herein have near optimal or optimal chemical stability (hydrolysis, and has a pH in the range of about pH 5.5 to about pH 7.5 to provide a cyclic amine derivative (e.g., deamidation, isomerization). In one embodiment, the formulations described herein have a pH range of about pH 5.7 to about pH 6.3. In one embodiment, the formulations described herein have a pH ranging from about 5.5 to about 6.5. In one embodiment, the formulations described herein have a pH range of about 5.7 to about 6.1. A preferred formulation has a pH of about 5.8. Another preferred formulation has a pH of about 6.0. Has a pH.

[0060] Suitably, the formulations described herein have a pH of about 5.5 to about pH 6.0, about pH 5.7 to about in the range of pH 6.0, or about pH 5.5, about pH 5.6, about pH 5.7, about pH 5.8, About pH5.9, about pH6.0, about pH6.1, about pH6.2, about pH6.3, about pH6. In embodiments, the p of the formulations provided herein is about pH 6.5 or about pH 7. H is 5.7 to 6.0, more suitably the formulation has a pH of about 5.8 or 6.0.

[0061] A formulation pH closer to approximately pH 7.4 may also be desirable for injection site tolerance. .

[0062] Ionic excipients Exemplary ionic excipients for use in the formulation include salts and charged amino acids. Ionic excipients may include combinations of salts and charged amino acids.

[0063] Exemplary charged amino acids include arginine and lysine.

[0064] Exemplary salts include salts of charged amino acids, such as the succinic acids of arginine and lysine. Salts include acetate and sulfate salts.

[0065] Further exemplary salts include, but are not limited to, sodium chloride, as well as sodium Other salts with ammonium, potassium, calcium, and magnesium, e.g., chloride, carbonate, etc. salts, sulfates, acetates, gluconates, lactates, malates, and in the field of parenteral administration The salts are as described herein, including other commonly used auxiliaries.

[0066] Suitably the salts are sodium chloride (NaCl), lysine hydrochloride, and arginine hydrochloride. In one embodiment, the salt is NaCl. In another embodiment, the salt is Al. ginine hydrochloride. In another embodiment, the salt is lysine hydrochloride.

[0067] The concentration of ionic excipients, suitably salts, in the pharmaceutical formulations described herein is generally about 50 mM. M to about 150 mM, more suitably about 50 mM to about 100 mM, about 60 mM to about 80 mM In the range, or about 50 mM, about 55 mM, about 60 mM, about 65 mM, about 70 mM, about 75 mM M, about 80 mM, about 85 mM, about 90 mM, about 95 mM, or about 100 mM (these (including any range or value within the range).

[0068] In one embodiment, the ionic excipient is present at a concentration of about 50 mM to about 125 mM.

[0069] In one embodiment, the ionic excipient is present at a concentration of about 50 mM to about 100 mM.

[0070] In one embodiment, the ionic excipient is present at a concentration of about 75 mM to about 100 mM.

[0071] In a suitable embodiment, the salt is present at a concentration of, for example, about 50 mM to about 100 mM, suitably about 70 NaCl concentration in mM.

[0072] In a suitable embodiment, the salt is present at a concentration of, for example, about 50 mM to about 100 mM, suitably about 80 Arginine hydrochloride at a concentration of 1 mM.

[0073] Buffer The formulations described herein suitably include one or more buffering agents. The term "buffering agent" as used herein refers to an excipient for maintaining the pH of the formulation. Exemplary buffering agents for use in the preparation include, but are not limited to, histidine, Histidine hydrochloride (histidine HCl), sodium succinate, sodium acetate, sodium acetate Thorium / Acetate, Sodium Phosphate, Citrate, Phosphate, Succinate, Glycine, and In one embodiment, buffers for use in the formulations described herein include salts of acetic acid, ethyl ether ... and ethyl ether. In one embodiment, the one or more buffering agents is sodium acetate / acetic acid. In one embodiment, the one or more buffering agents include histidine. histidine, histidine acetate, histidine citrate, histidine chloride, or histidine sulfate. In one embodiment, the one or more buffering agents are selected from buffering agents comprising histidine, histidine hydrochloride, or a combination thereof (histidine / histidine hydrochloride) In one embodiment, the one or more buffering agents are L-histidine / L-histidine hydrochloride. It is a hydrate.

[0074] The concentration of the buffer, suitably sodium acetate / acetic acid, in the pharmaceutical formulations described herein is generally Preferably about 10 mM to about 100 mM, more preferably about 15 mM to about 80 mM, more preferably about 25 mM to about 70 mM. 5mM, about 30mM to about 60mM, about 40mM to about 60mM, about 40mM to about 50mM, or about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 mM, about 65 mM, about 70 mM, or about 7 5 mM (including any range or value within these ranges).

[0075] In one embodiment, the one or more buffering agents are present at a concentration of, e.g., about 10 mM to about 50 mM. Suitably, L-histidine / L-histidine hydrochloride monohydrate at a concentration of about 30 mM.

[0076] The pH of the buffer is preferably in the range of pH 5.5 to pH 6.0.

[0077] It should be understood that the buffer may itself be an ionic excipient. In an embodiment, the buffering agent is an ionic excipient. In this embodiment, the concentration of the buffering agent is 5 0 mM, i.e., consistent with the concentrations of ionic excipients disclosed herein. The preferred concentration of the buffer in this embodiment is as described herein for the ionic excipients. As discussed elsewhere in the book.

[0078] In other words, in one embodiment, the ionic excipient also acts as a buffer in the formulation. In this embodiment, an additional buffer may or may not be present.

[0079] Sugars and surfactants The formulations described herein may contain sugars, such as, but not limited to, trehalose, Lactose, mannitol, mellibiose, melezitose, la Suitable include finose, mannotriose, stachyose, and sucrose. In the embodiment, trihydric or higher molecular weight sugar alcohols, e.g., glycerin, dextran , erythritol, glycerol, arabitol, xylitol, sorbitol, and Polyols such as mannitol can be used. Examples of reducing sugars include, but are not limited to, However, glucose, maltose, maltulose, isomaltulose, and Examples of non-reducing sugars include, but are not limited to, sugar alkanes, lactulose, and the like. Non-reducing glycol of polyhydroxy compounds selected from chocol and other linear polyalcohols Examples of sugar alcohols include, but are not limited to, trehalose, which is a sugar alcohol. However, the reduction of disaccharides such as lactose, maltose, lactulose, and maltulose is not observed. The glycosidic side group is a monoglycoside, which is a compound obtained by Further examples of sugar alcohols include: Examples include, but are not limited to, glucitol, maltitol, lactitol, and isomers. In one embodiment, the sugar is trehalose, lactose, mannitol, In certain embodiments, the glycerol is selected from the group consisting of sucrose, raffinose, and sucrose. In particular embodiments, trehalose is used as the sugar in the formulations described herein. Sucrose is used as the sugar in the formulations described herein.

[0080] Suitably, the amount of sugar, e.g., trehalose, in the formulations described herein is about 1% (w / v ) to about 10% (w / v). Unless otherwise specified, the percentages of ingredients used herein are % means weight / volume (w / v) %. In an exemplary embodiment, The amount of sugar in the drug formulation is about 1% (w / v) to about 8% (w / v), or about 2% (w / v) to Approx. 6% (w / v), approx. 2% (w / v) ~ approx. 5% (w / v), approx. 3% (w / v) ~ approx. 5% ( w / v), or about 1% (w / v), about 2% (w / v), about 3% (w / v), about 4% (w / v), approximately 5% (w / v), approximately 6% (w / v), approximately 7% (w / v), approximately 8% (w / v), About 9% (w / v), or about 10% (w / v) (and all values ​​and ranges within these ranges) (including

[0081] The formulations described herein suitably include a surfactant.

[0082] As used herein, the term "surfactant" refers to an organic substance that has an amphiphilic structure. that is, the amphiphilic structure is composed of groups with opposite solubility tendencies, typically oil-soluble hydrocarbons. Surfactants consist of a chain group and a water-soluble ionic group. Depending on the charge of the surface-active moiety, surfactants can be classified into anionic groups. Surfactants can be classified as ionic, cationic, and nonionic. It is used as a wetting agent, emulsifier, solubilizer, and sorbent for the preparation of various pharmaceutical formulations and biological materials. Polysorbates (e.g., polysorbate 20, 40) are often used as dispersants and dispersants. , 60, or 80); poloxamer (e.g., poloxamer 188); triton; Sodium octyl glycoside; lauryl, myristyl, linoleyl, or stearyl -aryl-sulfobetaine; lauryl-, myristyl-, linoleyl-, or stearyl- Sarcosine; Linoleyl-, Myristyl-, or Cetyl-Betaine; Lauramidoproline Pill-, Cocamidopropyl-, Linoleamidopropyl-, Myristamidopropyl-, Pa lumidopropyl- or isostearamidopropyl-betaine (e.g., lauroamide myristamidopropyl-, palmidopropyl-, or isostearamidopropyl Dopropyl-dimethylamine; Sodium methyl cocoyl taurate or methyl oleate Pharmacologically acceptable surfactants such as disodium lutaurate; and MONAQ UA(TM) Series (Mona Industries, Inc., Paterson , NJ), polyethyl glycol, polypropylene glycol, and ethylene and polypropylene glycol. Copolymers with propylene glycol (e.g., Pluronics, PF68, etc.) The surfactant may be used in the pharmaceutical formulations described herein. Suitably, the surfactant may be, for example, polyoxyethylene. Polysorbate 20, Polysorbate 40, Polysorbate 60, and Polysorbate 8 0. In one embodiment, the surfactant is polysorbate 80. do.

[0083] Suitably, the formulations described herein contain from about 0.001% to about 0.5% (w / v) of surfactant. a surfactant (suitably polysorbate 80), more suitably about 0.002% to about 0.1% Active agents, for example, from about 0.01% to about 0.2%, from about 0.02% to about 0.01%, from about 0.02% to about 0.02% % to about 0.07%, about 0.03% to about 0.06%, about 0.04% to about 0.06%, or Approximately 0.02%, approximately 0.025%, approximately 0.03%, approximately 0.035%, approximately 0.04%, approximately 0. 045%, approx. 0.05%, approx. 0.055%, approx. 0.060%, approx. 0.065%, approx. 0.0 7%, approx. 0.075%, approx. 0.08%, approx. 0.085%, approx. 0.09%, approx. 0.095% or about 0.1% surfactant, including any range or value therebetween. nothing.

[0084] The formulations described herein suitably include a surfactant and a sugar. The formulations described herein suitably include a sugar, a surfactant and one or more buffering agents. and one or more buffering agents. The formulations described herein suitably contain surfactants, sugars, and suitably one or more buffering agents.

[0085] The formulations described herein may also contain, for example, one or more sugars, salts, amino acids, polyamines, One or more additional excipients may also be included, including but not limited to, a chelating agent, an emulsifier, and / or a preservative. It may include.

[0086] Medicinal Use The formulations of the present invention are preferably pharmaceutical formulations. Suitably, the pharmaceutical formulations described herein are , "pharmaceutical acceptable" and therefore subject to federal or state regulatory authority or as required by the United States Pharmacopoeia, the European Pharmacopoeia, or other generally accepted It meets the necessary approval requirements as outlined in the Pharmacopoeias that are recognized by the FDA and is therefore approved for use in animals and, in particular, in humans. It is possible.

[0087] The present invention relates to a pharmaceutical formulation as described anywhere herein for use as a medicament. The present invention provides a method for treating a disease comprising administering to a subject a therapeutically effective amount of a compound as described anywhere herein. The present invention provides a pharmaceutical formulation as described anywhere in this specification. The present invention provides a method for treating a disease in a subject, comprising administering to an animal a compound as described anywhere in the present specification. A method of treating a subject by administering to the subject a therapeutically effective amount of a pharmaceutical formulation as described herein. Also provided herein.

[0088] As used herein, the term "subject" includes any human or non-human animal. The term "non-human animal" refers to all vertebrate animals, including, but not limited to, Mammals, including non-human primates, sheep, dogs, cats, horses, cows, chickens, amphibians, and reptiles This includes animals and non-mammals, hi one embodiment, the subject is a human.

[0089] Diseases include diabetes, cardiovascular disease, infectious diseases, rheumatoid arthritis, vasculitis, giant cell arteritis, glomerulonephritis, and Nephropathy, lupus nephritis, uveitis, atopic dermatitis, liver cirrhosis, psoriatic arthritis, chronic obstructive pulmonary disease The patient may be selected from the group consisting of obstructive pulmonary disease, severe asthma, neutrophilic asthma, and myeloid leukemia. .

[0090] In embodiments, the formulation is administered to the subject by subcutaneous administration or injection.

[0091] Suitably the formulation is a liquid formulation or a frozen formulation.

[0092] Also provided herein are methods for preparing a pharmaceutical formulation as described herein and administering the pharmaceutical formulation to a patient. Also disclosed herein is a method for preparing a pharmaceutical formulation, which includes appropriately filling a syringe into a pre-filled syringe. The instructions are provided in writing.

[0093] Suitably, the pharmaceutical formulations described herein are prepared in sterile water or in sterile water for injection. Resuspend in water to desired volume.

[0094] In an exemplary embodiment, the pharmaceutical formulation comprises from about 0.1 mL to about 20.0 mL, more suitably from about 0 .5mL to approx. 15.0mL, approx. 0.5mL to approx. 12.0mL, approx. 1.0mL to approx. 10.0 mL, about 1.0 mL to about 5.0 mL, about 1.0 mL to about 2.0 mL, or about 0.5 mL , approx. 0.6mL, approx. 0.7mL, approx. 0.8mL, approx. 0.9mL, approx. 1.0mL, approx. 1.1 mL, approx. 1.2mL, approx. 1.3mL, approx. 1.4mL, approx. 1.5mL, approx. 1.6mL, approx. 1 .7mL, approx. 1.8mL, approx. 1.9mL, approx. 2.0mL, approx. 2.1mL, approx. 2.2mL, Approx. 2.3mL, approx. 2.4mL, approx. 2.5mL, approx. 2.6mL, approx. 2.7mL, approx. 2.8m L, about 2.9 mL, or about 3.0 mL (including any range or value within these ranges) ) capacity.

[0095] In suitable embodiments, the pharmaceutical formulations described herein are liquid formulations, i.e., sterile water or A pharmaceutical formulation prepared in water for injection (WFI), which is a frozen formulation or It may also be a pre-lyophilized formulation.

[0096] The present invention also provides a method for preparing a formulation according to the present invention as described herein using only sterile water. The antibody:ionic excipient ratio is adjusted to provide a lyophilized cake that can be reconstituted. It should be understood that the formulation in the lyophilized cake is the same as that after lyophilization. In the present study, the molar ratio of ionic excipient:antibody ranged from 450:1 to 40:1. If lyophilized, the concentrations of the formulations provided herein are those after reconstitution and Thus, the so-called "drug" concentration. For example, when the semi-reconstitution method is used ( (If half the amount of water removed during lyophilization is added back during reconstitution), after reconstitution, the antibody concentration The concentration was twice as high as that before freeze-drying, i.e., the concentration was 2 times higher than that in the so-called "drug-substance" composition before freeze-drying. Thus, the present invention provides a method for freeze-drying a lyophilized cake. The present invention further provides a composition that can be used to freeze-dry a lyophilized cake using only sterile water. It is understood that the composition can be reconstituted into a formulation according to the invention as described herein. Suitable reconstitution methods will be known to those skilled in the art.

[0097] In embodiments, a liquid pharmaceutical formulation as described herein is provided, prepared under appropriate conditions. It is desirable to prepare a frozen formulation by freezing the liquid. The formulation is heated to below 0°C, more suitably at about -20°C, about -40°C, about -60°C, or suitably at The pharmaceutical formulation may be provided by freezing at about -80° C. The pharmaceutical formulation may also be provided as a liquid formulation. and stored at about 2°C to about 8°C, or at about 2°C, about 3°C, about 4°C, about 5°C, or about 6°C. , about 7°C, or about 8°C.

[0098] Suitable protocols for preparing lyophilized pharmaceutical formulations from liquid and / or frozen formulations Collages and methods are known in the art.

[0099] Stability of the formulation In an exemplary embodiment, the formulations described herein are administered at room temperature or in a temperature range of about 2° C. to about 8° C. The composition is stable for long-term storage at temperatures ranging from 100° C. to 50° C., suitably at about 5° C. As used herein, room temperature generally refers to The temperature range is from about 22° C. to about 25° C. Suitably, the pharmaceutical formulation is maintained at about 2° C. to about 8° C. (e.g., 5° C. The term "storage period" as used herein refers to a storage period of at least six months. The term "stable" (or "stability") refers to a monoclonal antibody, suitably an IgG4 Monoclonal antibodies, pharmaceutical formulations resist aggregation, degradation, half-antibody formation, and / or fragmentation The stability of a monoclonal antibody is high compared to a reference. High performance size exclusion chromatography (HPSEC), static light scattering (SLS), Fourier transform FTIR, Circular Dichroism (CD), Urea Denaturation Technique (Urea Unfo lding technique, intrinsic tryptophan fluorescence, differential scanning calorimetry, and and / or the degree of aggregation, degradation, half-antibody formation, or fragmentation as measured by ANS binding techniques. It can be evaluated by fragmentation.

[0100] The overall stability of pharmaceutical formulations containing monoclonal antibodies may be affected by, for example, the presence of isolated antigen molecules. by various immunological assays, including ELISA and radioimmunoassay using It can be evaluated.

[0101] As used herein, the phrase "low to undetectable levels of aggregation" refers to high performance by size exclusion chromatography (HPSEC) or static light scattering (SLS) techniques Measured, about 5% by weight or less, about 4% by weight or less, about 3% by weight or less, about 2% by weight or less, about 1 % by weight or less, or about 0.5% by weight or less of protein aggregation. Suitably, the pharmaceutical formulation has ≦5.0% aggregation, more suitably ≦4.0% aggregation, ≦3.0% 0.05% agglutination, ≦2.0% agglutination, ≦1.0% agglutination, or 0.5% agglutination. , liquid pharmaceutical formulations and / or frozen pharmaceutical formulations should have ≦5.0% aggregation, more suitably ≦4. 0% aggregation, ≤3.0% aggregation, ≤2.0% aggregation, ≤1.0% aggregation, or 0.5% shows aggregation.

[0102] As used herein, the phrase "low to undetectable levels of fragmentation" refers to, e.g., For example, as determined by HPSEC or reduced capillary gel electrophoresis (rCGE). In such a single peak, the concentration is about 80% or more, about 85% or more, about 90% or more, about 95% or more, This refers to pharmaceutical preparations that contain 98% or more, or approximately 99% or more of total monoclonal antibodies. Degraded monoclonal antibodies or their non-degraded fragments, which account for more than approximately 5% of all monoclonal antibodies , more than about 4%, more than about 3%, more than about 2%, more than about 1%, or more than about 0.5%. Fragmentation can be adequately measured in IgG4 monoclonal antibodies. Without wishing to be bound by theory, it is believed that the decrease in autoaggregation corresponds to an increase in kD value. This is believed to be due to improved colloidal stability, as evidenced by the above. In some embodiments, the formulations described herein can be measured by visual observation, light scattering, nephelometry, or turbidimetry. There is a reduction in opalescence and a reduction in phase separation as detected by the method.

[0103] Further embodiments, features, and advantages of the embodiments, as well as the structure and method of the various embodiments, are described below. The operation is described in detail below with reference to the accompanying drawings.

[0104] Working Example Example 1 - IgG4 formulation The challenge in formulating antibodies with low or neutral pI values ​​is that these antibodies have pI values ​​between 5.5 and 7.5. pH outside the range generally required to increase protein charge and colloidal stability Further instability is observed when the drug is formulated in acidic pH. , an increase in fragmentation rate, a decrease in conformational stability, and an increase in aggregation are observed. H may be prone to increased oxidation, deamidation, and fragmentation, as well as incompatibility with glassware. IgG4 antibodies typically have low or neutral pI values, making such It is particularly useful for investigating instability.

[0105] The following is a method for optimizing the storage stability of a monoclonal antibody with a neutral pI and the above-mentioned The formulations described herein were developed to overcome the physical instability of neutral pH. This article details how this can be done.

[0106] As described herein, the formulations combine neutral pH with ionic excipients such as salts. Optionally, sugars can also be used in the formulation, which may has been shown to provide further improvements.

[0107] Sugars (sucrose and trehalose are examples) (in combination with ionic excipients) ) can further enhance conformational stability; ionic excipients (e.g., sodium chloride) , lysine hydrochloride, and arginine hydrochloride) are used to stabilize the colloidal structure of monoclonal antibody molecules. In addition, the neutral pH of the formulation (approximately pH 6) also enhances the acidic and basic degradation described above. These formulations provide superior overall efficacy for these monoclonal antibodies. Other suitable components of the formulation include a buffer with a neutral pKa (e.g., Examples include NaAC, histidine HCl, and sodium phosphate.

[0108] As described herein and listed in Table 1, CAM-3001 (anti-GM-CSFR α monoclonal antibody), two anti-IL-13 monoclonal antibodies, and anti-C5 / C5 aThe monoclonal antibodies are IgG4 with neutral pI values ​​and were therefore selected for this study. I chose it for that reason.

[0109] [Table 1]

[0110] CAT-354 specifically binds to human interleukin 13 (IL-13) and inhibits I It is a human antibody of the IgG4 subclass that blocks interaction with the L-13 receptor. The DNA and derived amino acid sequences of the light and heavy chains of T-354 are Provided in "Error! Reference source not found" and "Error! Reference source not found" "Error! Reference source not found" and "Error! Reference source not found" are H and V L The sequence is labeled and the six CDRs are underlined. is a human monoclonal IgG4 ( The antibody is a λ light chain antibody (containing oligosaccharides). The antibody is made up of two α-terminal fragments of approximately 49,500 Da each. It consists of an identical heavy chain and two identical light chains of approximately 22,500 Da each. CAT-3 54 is a fucosylated biantennary complex and a high mannose nucleotide linked to each heavy chain at Asn-299. The average size of the oligosaccharide moieties is about 1,650 D per heavy chain. It is a.

[0111] CAM-3001 inhibits the granulocyte-macrophage colony-stimulating factor receptor α (GM-CSF CAM-3001 is an antibody that binds to CAM-3001 (Rα), the disclosure of which is incorporated herein by reference. The invention is disclosed in International Publication No. WO 2007 / 110631, which is incorporated herein by reference. The heavy chain CDRs (HCDRs) of -3001 are shown in WO 2007 / 110631. The light chain CDR (LC CDR) of CAM-3001 is disclosed in SEQ ID NO: 53 to 55. DR) are listed as SEQ ID NOs: 58 to 60 in the pamphlet of International Publication No. WO 2007 / 110631. The heavy chain variable region (VH) of CAM-3001 is disclosed in International Publication No. 2007 / 013366. It is disclosed as SEQ ID NO: 52 in the pamphlet of 110631. The light chain variable region (VL) is shown in SEQ ID NO: It is disclosed as 218.

[0112] As shown in FIG. 2, in the presence of salt at a concentration of 100 mM, the aggregation rate is It increases when the molecule is at pH 6 and pH 7, but it decreases when the molecule is at pH 8 and pH 9.

[0113] To achieve the most stable formulations, a combination of conformational and colloidal stability is required. By testing, the solution properties and diffusion interaction parameters (k D The correlation between the D is measured as an index of colloidal stability and is DSC was investigated as a measure of conformational stability. k for antibody at various pH values D FIG. 3B shows the results of adding salt at a concentration of 100 mM. The k values ​​of monoclonal antibodies at various pH levels were examined after addition of D Shows low e In the on-strength, k D Generally, the pH becomes more negative with increasing pH. k for all molecules D becomes less likely to become negative.

[0114] For the results shown in Figure 4, salt was added to the formulation at a concentration of 100 mM to examine colloidal stability. In general, colloidal stability is decreased at pH 5, whereas colloidal stability is increased at pH 6 and pH 7. Note that the quality is improved.

[0115] In the results shown in Figure 5, the aggregation rate data at 40°C are The results were obtained for formulations containing salts close to the pI (pH 6 or 7) compared with formulations containing salts farther from the pI. The results show reduced aggregation compared to the non-treated formulation.

[0116] From the results of the aggregation rates shown in Figures 6 and 7, it is clear that charged amino acids are ion-stable near the molecular pI. It can also act as a stabilizing agent, and in some cases may be more stabilizing than NaCl. It can be seen that...

[0117] To determine the effect on IgG4 stability, salts were added to histidine-based buffers. The following buffer systems were tested: control buffer (25 mM histidine, 7% sucrose sucrose, pH 6); test buffer (25 mM histidine, 7% sucrose; 100 mM Na The effect of salt on the composition (pH 6) and appearance is summarized in Table 2 below.

[0118] [Table 2]

[0119] As demonstrated above, the addition of salt reduced the rate of aggregation and monomer loss, improving the formulation. The appearance of has been improved.

[0120] In summary, formulations containing salt and with or without sugar are less opalescent and in some cases reduces phase separation and provides comparable or better results than formulations containing sucrose alone Provides stability.

[0121] Freeze-thaw testing showed no significant changes in product quality after three freeze-thaw cycles, e.g. It was shown that there were no invisible particles. In summary, the addition of both salt and sugar This improves the stability of IgG4 molecules even when formulated at pH levels close to their pI. It was good.

[0122] Example 2 - IgG1 formulation MEDI8897 is a human IgG1κ-YTE monoclonal antibody directed against the RSV-F protein. It is a monoclonal antibody. It has three amino acid substitutions in the CH2 region of the Fc domain (M252Y / S254T / T256E; referred to as YTE) was introduced into the serum of MEDI8897. The sequence information of MEDI8897 is shown in Figures 8 and 9. MEDI8897 The pI of this compound was measured by cIEF to be 6.4-6.7, with a major peak at 6.4. The pI is a measure of the formulation buffer that may indicate potential problems with manufacturing, formulation, and storage stability. This overlaps with the range (5.5 to 6.5).

[0123] The thermal stability of MEDI8897 was measured by differential scanning calorimetry. The Tml was found to be 61°C, whereas the Tml was found to be 61°C. Tml above 50°C indicates that the molecule This suggests that it has acceptable colloidal stability.

[0124] Stability Summary MEDI889 in standard buffer (25 mM histidine, 7% sucrose, pH 6.0) When 7 was added, phase separation was observed at 2-8°C. The upper layer had a protein concentration of 75mg / ml. The bottom layer had 125 mg / ml, while the bottom layer had 125 mg / ml. Upon equilibration at 25°C, two different Phase separation at 2-8°C was observed at pH 6.0 of the formulation. This is believed to be due to the close pI of MEDI8897. MEDI8897 stability, targeting conditions that prevent phase separation of MEDI8897 at 1 Exploratory studies were initiated to find a more suitable formulation buffer for evaluation.

[0125] Standard buffers with pH below 5.9 or above 6.7 (25 mM histidine, 7% sucrose Formulation with 75 mM DMSO in standard buffers between pH 5.0 and 6.7 mitigated phase separation. Addition of NaCl also mitigated phase separation. Finally, acetate buffers at pH values ​​far from the pI and phosphate buffer also mitigated phase separation. Based on prior knowledge of the mAb with a pI of 100 mM H s / HisHCl, 75mM NaCl, 4% sucrose, 0.02% PS80, pH 6 .0) was selected.

[0126] kD Test For the initial kD screening, all samples were incubated at 25°C for 2–10 mg / ml. The assay was performed in a 10 mM histidine-based buffer at pH 5.5. This buffer is used because it is more soluble in 5.5 and facilitates DLS measurements that are sensitive to insoluble particles. The agents were selected to replace pH 6.0. Arginine-HCl, Lysine-HCl, and Na Ionic excipients containing Cl were added at 10 mM, 25 mM, 50 mM, 75 mM, and 100 mM. In addition, proline, alanine, Na 2 SO 4 , and histidine , only the 100 mM concentration was evaluated. Finally, 2%, 4%, and 6% sucrose were evaluated. To determine whether sucrose affects protein-protein interactions, All conditions were compared to a buffer control (25 mM histidine, pH 5.5).

[0127] The control samples had hydrodynamic radii that increased from 6.2 to 7.8 nm at 2 to 10 mg / ml. They showed different protein-protein interactions. HCl and NaCl have hydrodynamic size distributions over the concentration range of 2-10 mg / ml. As evidenced by the lack of an increase in There was no additional effect between 25 and 100 mM. At 100 mM, proline and alanine produced PPI similar to that of the control. However, Na 2 SO 4 and histidine reduced PPI. Finally, sucrose concentration had no effect on PPI. This data was consistent with the results obtained with charged excipients (Arg-HCl, Lys- HCl, histidine, and Na 2 SO 4 ) reduces protein-protein interactions However, neutral excipients (sucrose, proline, alanine) did not reduce PPI. Therefore, the addition of ionic excipients at pH 5.5 resulted in a 100 mg / ml The phase separation was reduced.

[0128] Stability evaluation at 40℃ Based on the kD screening, several conditions were selected for stability evaluation at 40°C. Table 3 summarizes the formulation conditions and the one-month degradation rates observed at 40°C.

[0129] [Table 3]

[0130] This study demonstrates that arginine and lysine are more stabilizing than NaCl. Furthermore, 75 mM and above appears to stabilize against aggregation. Based on this study, The most lyo-friendly excipient that stabilizes arginine was selected and advanced to the next series of tests.

[0131] Drug stability against last lyophilization cycle / representative material The stability of the drug was evaluated. 30 mM L-histidine / L-histidine hydrochloride monohydrate , 80 mM L-arginine hydrochloride, 120 mM sucrose, 0.04% (w / v) 3 for formulations after reconstitution at 100 mg / ml in polysorbate 80, pH 6.0 Data was collected for three months. The results are shown in Figure 10. Storage at 2 to 8°C was showed virtually no change in lyophilization time, supporting the suitability of the formulation and lyophilization cycle for clinical use. Therefore, these data indicate that the formulation provides adequate stability and solubility, and This is the first time that it has been demonstrated to be suitable for human clinical use.

[0132] [Table 4]

[0133] Example 3 - IgG4 formulation Formulations of antibody MEDI578 were tested at pH 6. MEDI578 has a pH of 6.3 to 6.8. It is an IgG4 monoclonal antibody with a pI

[0134] The results are shown in Figure 11.

[0135] Example 4 - IgG4 formulation All formulations tested were polysorbate-free and contained 100 mg / ml MEDI57. 8, 20 mM histidine, pH 6.5. MEDI578 was 6.3–6. It is an IgG4 monoclonal antibody with a pI of 8.

[0136] [Table 5]

[0137] FIG. 12 shows the purity by size exclusion chromatography.

[0138] Figure 13 shows the reduction of subvisible particles in formulations containing ionic excipients under thermal stress conditions. The colloidal stability is improved.

[0139] All publications, patents, journal articles, and other materials cited in this application are hereby incorporated by reference. will be incorporated into the subsection.

[0140] The present invention will now be more fully described in connection with certain embodiments thereof with reference to the accompanying drawings. However, it should be understood that various changes and modifications may be apparent to those skilled in the art. Such changes and modifications are intended to be covered by the appended claims without departing from the scope of the invention. It is to be understood that such disclosure is within the scope of the present invention as defined herein.

Claims

1. i. an anti-GM-CSFRα antibody; and ii. Ionic excipients The formulation comprises an anti-GM-CSFRα antibody having a pI in the range of pH 6.0 to pH 7.5 and the VH and VL sequences of CAM-3001, wherein the VH sequence of CAM-3001 has the amino acid sequence shown in SEQ ID NO: 11 and the VL sequence of CAM-3001 has the amino acid sequence shown in SEQ ID NO: 12, the anti-GM-CSFRα antibody is present in a concentration of 50 mg / ml to 200 mg / ml, the ionic excipient is NaCl and is present in a concentration of 50 mM to 100 mM, the formulation has a pH of 5.5 to 6.5, and The formulation, wherein the anti-GM-CSFRα antibody is an IgG4 monoclonal antibody.

2. 2. The formulation of claim 1, wherein the aggregation rate of the antibody in the formulation is reduced compared to the aggregation rate of the same antibody in the same formulation without the ionic excipient.

3. The formulation according to claim 1 or 2, wherein the anti-GM-CSFRα antibody has a pI in the range of pH 6.4 to pH 7.

5.

4. The formulation according to any one of claims 1 to 3, wherein the anti-GM-CSFRα antibody is present in the formulation in a concentration of from 100 mg / ml to 200 mg / ml.

5. 5. The formulation of claim 4, wherein the monoclonal antibody is present in the formulation at a concentration of 100 mg / ml or 150 mg / ml.

6. The formulation according to any one of claims 1 to 5, wherein the formulation has a pH of pH 5.

8.

7. The formulation of any one of claims 1 to 6, wherein the formulation further comprises a sugar.

8. The formulation of any one of claims 1 to 7, wherein the formulation further comprises one or more buffering agents.

9. 9. The formulation of any one of claims 1 to 8, wherein the formulation further comprises a surfactant at a concentration of 0.02% (w / v) to 0.07% (w / v).

10. 2. The formulation of claim 1, comprising 150 mg / ml of anti-GM-CSFRα antibody, 50 mM sodium acetate / acetic acid, 106 mM trehalose dehydrate, 70 mM sodium chloride, and 0.05% (w / v) polysorbate 80, and having a pH of pH 5.

8.

11. A pharmaceutical formulation according to any one of claims 1 to 10 for use as a medicament or for use in the treatment of a disease.

12. The formulation of any one of claims 1 to 6, wherein the ionic excipient is present in a concentration of 70 mM.

13. 8. The formulation of claim 7, wherein the sugar is trehalose or sucrose, and the sugar is present at a concentration of 100 mM to 140 mM.

14. 9. The formulation of claim 8, wherein the one or more buffering agents are selected from histidine, histidine hydrochloride, and histidine / histidine hydrochloride.

15. 10. The formulation of claim 9, wherein the surfactant is polysorbate or polysorbate-80.

Citation Information

Patent Citations

  • Anti-IL-13 antibody preparations and their use

    JP2010515742A

  • Formulations of antibodies and FC fusion molecules using polycations

    JP2010536786A

  • Formulation of a stable IgG4-based binder

    JP2015514090A

  • Antibody preparations

    JP2015521593A

  • Anti-il-7r antibody composition

    JP2016104715A